RT Journal Article
SR Electronic
T1 Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.24.22271475
DO 10.1101/2022.02.24.22271475
A1 Carmona-Rivera, Carmelo
A1 Zhang, Yu
A1 Dobbs, Kerry
A1 Markowitz, Tovah E.
A1 Dalgard, Clifton L.
A1 Oler, Andrew J.
A1 Claybaugh, Dillon R.
A1 Draper, Deborah
A1 Truong, Meng
A1 Delmonte, Ottavia M.
A1 Licciardi, Francesco
A1 Ramenghi, Ugo
A1 Crescenzio, Nicoletta
A1 Imberti, Luisa
A1 Sottini, Alessandra
A1 Quaresima, Virginia
A1 Fiorini, Chiara
A1 Discepolo, Valentina
A1 Vecchio, Andrea Lo
A1 Guarino, Alfredo
A1 Pierri, Luca
A1 Catzola, Andrea
A1 Biondi, Andrea
A1 Bonfanti, Paolo
A1 Harlowe, Maria Cecilia Poli
A1 Espinosa, Yasmin
A1 Astudillo, Camila
A1 Rey-Jurado, Emma
A1 Vial, Cecilia
A1 de la Cruz, Javiera
A1 Gonzalez, Ricardo
A1 Pinera, Cecilia
A1 Mays, Jacqueline W.
A1 Ng, Ashley
A1 Platt, Andrew
A1 ,
A1 ,
A1 Drolet, Beth
A1 Moon, John
A1 Cowen, Edward W.
A1 Kenney, Heather
A1 Weber, Sarah E.
A1 Castagnoli, Riccardo
A1 Magliocco, Mary
A1 Stack, Michael A.
A1 Montealegre, Gina
A1 Barron, Karyl
A1 Hewitt, Stephen M.
A1 Arkin, Lisa M.
A1 Chertow, Daniel S.
A1 Su, Helen C.
A1 Notarangelo, Luigi D.
A1 Kaplan, Mariana J.
YR 2022
UL http://medrxiv.org/content/early/2022/03/03/2022.02.24.22271475.abstract
AB Dysregulation in neutrophil extracellular trap (NET) formation and degradation may play a role in the pathogenesis and severity of COVID-19; however, its role in the pediatric manifestations of this disease including MIS-C and chilblain-like lesions (CLL), otherwise known as “COVID toes”, remains unclear. Studying multinational cohorts, we found that, in CLL, NETs were significantly increased in serum and skin. There was geographic variability in the prevalence of increased NETs in MIS-C, in association with disease severity. MIS-C and CLL serum samples displayed decreased NET degradation ability, in association with C1q and G-actin or anti-NET antibodies, respectively, but not with genetic variants of DNases. In adult COVID-19, persistent elevations in NETs post-disease diagnosis were detected but did not occur in asymptomatic infection. COVID-19-affected adults displayed significant prevalence of impaired NET degradation, in association with anti-DNase1L3, G-actin, and specific disease manifestations, but not with genetic variants of DNases. NETs were detected in many organs of adult patients who died from COVID-19 complications. Infection with the Omicron variant was associated with decreased levels of NETs when compared to other SARS-CoV-2 strains. These data support a role for NETs in the pathogenesis and severity of COVID-19 in pediatric and adult patients.Summary NET formation and degradation are dysregulated in pediatric and symptomatic adult patients with various complications of COVID-19, in association with disease severity. NET degradation impairments are multifactorial and associated with natural inhibitors of DNase 1, G-actin and anti-DNase1L3 and anti-NET antibodies. Infection with the Omicron variant is associated with decreased levels of NETs when compared to other SARS-CoV-2 strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by the Intramural Research Program at NIAMS/ (ZIAAR041199 to MJK), NIAID (ZIA AI001270-01 to LDN and ZIAAI001265 to HCS), NIDCR (ZIADE000747 to JM),the Wisconsin Partnership Program 2020 Strategic COVID-19 Grant (to LA), FONDECYT 11181222 (to MCP), ANID 0999 (to MCV and MCP), and Regione Lombardia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All individuals were enrolled in protocols approved by local Institutional Review Boards (IRBs: Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile (protocol 2020-41); Comitato Etico Interaziendale A.O.U. Citta della Salute e della Scienza di Torino, Turin, Italy (protocol 00282/2020); Ethics Committee of the University of Naples Federico II, Naples, Italy (protocol 158/20); Comitato Etico Provinciale of Brescia, Italy (protocol NP4000); University of Milano Bicocca, San Gerardo Hospital, Monza; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA (protocols NCT04582903, NCT03394053 and NCT03610802); University of Wisconsin Madison (protocol 2020-0667).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study work are contained in the manuscript